Medical management of unmethylated MGMT-promoter recurrent GBM is typically a multimodality treatment plan consisting of maximal safe surgical resection (when possible), followed by radiotherapy with concomitant and maintenance therapy with Temozolomide (TMZ) and/or other secondary chemotherapies,3,22,23 which continually increases treatment morbidity leading to further cost with diminishing returns on the outcome. This evidence concerns the gene MGMT and glioblastoma.